Clinical Trial Update: Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated escalating doses of lenalidomide in combination with rituximab and fludarabine in untreated chronic lymphocytic leukemia. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Fludarabine (Fludarabine)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1, Phase 2 | Status: COMPLETED